Causes of AA amyloidosis: a systematic review

@article{Brunger2019CausesOA,
  title={Causes of AA amyloidosis: a systematic review},
  author={Anne Floor Brunger and Hans L A Nienhuis and Johan Bijzet and Bouke P C Hazenberg},
  journal={Amyloid},
  year={2019},
  volume={27},
  pages={1 - 12}
}
Abstract From a clinical perspective, there is a need for a reliable and comprehensive list of diseases causing AA amyloidosis. This list could guide clinicians in the evaluation of patients with AA amyloidosis in whom an obvious cause is lacking. In this systematic review, a PubMed, Embase and Web of Science literature search were performed on causes of AA amyloidosis published in the last four decades. Initially, 4066 unique titles were identified, but only 795 full-text articles and letters… 
View on Taylor & Francis
tandfonline.com
38 Citations
Highly Influential Citations
2
Background Citations
7
Methods Citations
1

38 Citations

Citation Type

Citation Type

AA Amyloidosis in the Course of HIV Infection: A Report of 19 Cases Including 4 New French Cases and a Comprehensive Review of Literature
TLDR
HIV is probably not an independent risk factor for AA amyloidosis, but it is a rare condition in HIV patients with common renal involvement and significant risk of progression to chronic renal insufficiency.
Systemic amyloidosis from A (AA) to T (ATTR): a review
TLDR
Each type of systemic amyloidosis is reviewed to provide the practitioner with practical tools to improve diagnosis and management of these rare disorders.
Gout and AA-Amyloidosis: A Case-Based Review
TLDR
Clinicians should be aware that patients may have atypical combinations of diseases like gout and amyloidosis, and be aware of the effectiveness of different treatment options such as lifestyle biologic agents or other medicines with anti-inflammatory properties.
Diagnosis of amyloid beyond Congo red.
  • M. Picken
  • Medicine, Biology
    Current opinion in nephrology and hypertension
  • 2020
TLDR
Despite significant advances in the treatment of the systemic amyloidoses, outcomes remain poor, primarily due to delays in diagnosis, and Precise diagnosis of the amyloids protein type is critical for treatment selection.
Yet another amyloidosis
  • R. Means
  • Medicine
    Journal of Investigative Medicine
  • 2021
TLDR
A review article discussing the clinical features, pathogenesis, and current understanding of an underrecognized but relatively frequent amyloidosis disorder caused by the deposition of leukocyte chemotactic factor 2 (LECT2).
Amyloidosis of the urinary bladder: a systematic review and a proposed management algorithm.
Obesity-induced AA amyloidosis: A diagnosis of exclusion
A 47-year-old woman with morbid obesity (body mass index: 41 kg/m2) and a history of hypertension, pulmonary embolism and successfully treated gout (one year ago) presented with nephrotic syndrome…
A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis.
Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature
TLDR
A 31-year-old female patient from India presented to the authors' institution with proteinuria, and the diagnosis of Takayasu arteritis (TA) was made, considering the patient’s characteristics and clinical presentation.
Pulmonary amyloidosis mimicking interstitial lung disease and malignancy - A case series with a review of a pulmonary patterns
...
...

References

SHOWING 1-10 OF 79 REFERENCES
The changing face of AA amyloidosis: a single center experience
  • S. Girnius, L. Dember, G. Doros, M. Skinner
  • Medicine
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • 2011
TLDR
Survival comparisons showed that the group with traditional causes of AA had a nonstatistically significant trend toward shorter survival, which is similar to that of other atypical causes of inflammation.
AA amyloidosis: Mount Sinai experience, 1997-2012.
TLDR
A retrospective chart review of patients seen at Mount Sinai during the period of 1997-2012 confirms the increasing number of patients being seen with idiopathic AA amyloidosis and confirms the dominance of renal disease in this population.
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.
  • S. Said, S. Sethi, S. Nasr
  • Medicine, Biology
    Clinical journal of the American Society of Nephrology : CJASN
  • 2013
TLDR
The newly identified leukocyte chemotactic factor 2 amyloidosis form was the most common of the rarer causes of renal amyloidalosis and was associated with lower serum creatinine, higher degree of proteinuria, and amyloids spicules.
Obesity is a significant susceptibility factor for idiopathic AA amyloidosis
  • N. Blank, U. Hegenbart, S. Schönland
  • Medicine, Biology
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • 2018
TLDR
Obesity, age and the SAA1 polymorphism are susceptibility factors for idiopathic AA amyloidosis, which might be an emerging problem in the ageing and increasingly obese population.
Natural history and outcome in systemic AA amyloidosis.
TLDR
The effects of renal dysfunction dominate the course of AA amyloidosis, which is associated with a relatively favorable outcome in patients with SAA concentrations that remain in the low-normal range (<4 mg per liter).
AA amyloidosis: basic knowledge, unmet needs and future treatments.
TLDR
Although the incidence of AA in rheumatoid arthritis and other chronic arthritides has continuously decreased over the past ten years, thanks to the increasing availability of more effective anti-inflammatory and immunosuppressive therapies, AA remains a life-threatening disease with several areas of uncertainty and unmet needs, deserving continuous efforts at prevention and effective treatment.
AA protein in a case of "primary" or "idiopathic" amyloidosis.
Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview.
TLDR
Genetic, biologic, and clinical factors underlying susceptibility to the development of AA amyloidosis in patients with chronic rheumatic disorders are reviewed and a critical interpretation is provided that also is supported by the well-characterized mouse model of the disease.
Risk factors for AA amyloidosis in Germany
  • N. Blank, U. Hegenbart, S. Schönland
  • Medicine, Biology
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • 2015
TLDR
Risk factors for AA amyloidosis are the presence of a hereditary autoinflammatory or chronic rheumatic disease, elevated C-reactive protein and SAA serum levels, a long delay of a sufficient therapy, an advanced age and the SAA1α/α genotype.
Pathophysiology and treatment of systemic amyloidosis
TLDR
Advances in the understanding of the pathogenesis of systemic amyloidosis have resulted in the identification of new therapeutic targets, and several drugs with novel mechanisms of action are currently under development.
...
...